MedTrace Logo

Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients

NCT06343428 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-05-06

No results posted yet for this study

Summary

The 2017 World Health Organization (WHO) introduced a new category of high-grade, well-differentiated neuroendocrine neoplasms (NENs) that called neuroendocrine tumors (NETs) G3 in pancreatic NENs classification and, then, in 2019, for all gastro-entero-pancreatic (GEP) tract NENs.

The new classification made it possible to separate NETs G3 from high-grade, poorly-differentiated, NENs that are called neuroendocrine carcinomas (NECs).

However, in clinical practice, we observed that several clinical, pathological and radiological differences are arising among NET G3 patients, suggesting that a multiparametric definition of NET G3 is needed.

Conditions

  • Neuroendocrine Neoplasm

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Francesca Spada, MD · Istituto Europeo di Oncologia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-19
Primary Completion
2024-07-19
Completion
2026-07-19

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06343428 on ClinicalTrials.gov